TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03309215

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental stimulation with nickel discs
Description: All participants will be exposed to 8 metal discs, 3 cm in diameter, 4 on each arm, placed on the volar side of the forearms (figure 1). Three of the metallic discs consists of \>99 wt.% nickel one consist of \>99wt.% Aluminium.The latter is used as a negative control. The discs will be applied under occlusion and with initial pressure and friction.~One metallic disc with nickel, and one with aluminium, will be randomized for the earlobes on the patients with nickel allergy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental stimulation with nickel discs
Description: All participants will be exposed to 8 metal discs, 3 cm in diameter, 4 on each arm, placed on the volar side of the forearms (figure 1). Three of the metallic discs consists of \>99 wt.% nickel one consist of \>99wt.% Aluminium.The latter is used as a negative control. The discs will be applied under occlusion and with initial pressure and friction.~One metallic disc with nickel, and one with aluminium, will be randomized for the earlobes on the patients with nickel allergy
Study: NCT00535236

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V212
Description: 0.65 ml V212 in 4 dose regimen. Treatment period of 125 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V212
Description: 0.65 ml V212 in 4 dose regimen. Treatment period of 125 days
Study: NCT00184444

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypoxic interval training
Description: 4 x 4 minutes interval training in hypoxic air, 3 times per week at 90-95% HR max

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normoxic interval training
Description: 4 x 4 minutes normoxic interval training, 3 times per week at 90-95% HR max
Study: NCT01319344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Description: 25 mg o.d. per os
Study: NCT00824850

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent Pneumococcal Conjugate Vaccine
Description: single injection, single dose, single site, 0.5 mL per dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent Pneumococcal Conjugate Vaccine
Description: single injection, single dose, single site, 0.5 mL per dose.
Study: NCT02367794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody
Description: Atezolizumab 1200 milligrams (mg) intravenous infusion (IV) on day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody
Description: Atezolizumab 1200 milligrams (mg) intravenous infusion (IV) on day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin area under the concentration curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle for 4 or 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin area under the concentration curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle for 4 or 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin area under the concentration curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle for 4 or 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Nab-paclitaxel 100 milligrams per meter squared (mg/m\^2) IV on Day 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-Paclitaxel
Description: Nab-paclitaxel 100 milligrams per meter squared (mg/m\^2) IV on Day 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 200 mg/m\^2 IV on Day 1 of each 21-day cycle for 4 or 6 cycles. Participants of Asian race/ethnicity will be administered paclitaxel 175 mg/m\^2 IV.
Study: NCT03455140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG- BCT-100
Description: PEGylated recombinant human arginase 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG- BCT-100
Description: PEGylated recombinant human arginase 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG- BCT-100
Description: PEGylated recombinant human arginase 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG- BCT-100
Description: PEGylated recombinant human arginase 1
Study: NCT02010684

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empowerment and CBT Classes
Description: Participants randomized to the intervention arm will receive a manual with 3 CBT modules and 1 Diabetes Empowerment module. CBT Module 1 covers Understanding Depression and Diabetes, Module 2 How Thoughts Affect Your Mood and Diabetes Care, Module 3 How Activities Affect Your Mood and Diabetes Care. The Diabetes Empowerment Module covers topics including the following: food, exercise, medicine, diabetes and your health, social support, communication skills, and community resources.
Study: NCT02871245

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Study: NCT01043588

Intervention type: PROCEDURE
Group type: OTHER
Intervention: TURP
Description: TransUrethral Resection of the Prostate

Intervention type: PROCEDURE
Group type: OTHER
Intervention: PVP
Description: Photo selective Vaporization of the Prostate
Study: NCT00773890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRF-1101
Description: once daily treatment with 300 mg orally for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily treatment with TRF-1101 vehicle for 12 weeks
Study: NCT02390180

Intervention type: OTHER
Intervention: Tasting solutions
Description: Participants will taste a variety of food grade compounds including: hexenoic acid, decenoic acid, oleic acid, linoleic acid, glucose, fructose, salt, citric acid, acetic acid, quinine, urea, caffeine, sucrose octaacetate, propylthiouracil, phenylthiocarbamide, monosodium glutamate, and inosine monophosphate.

Intervention type: OTHER
Intervention: Tasting solutions
Description: Participants will taste a variety of food grade compounds including: hexenoic acid, decenoic acid, oleic acid, linoleic acid, glucose, fructose, salt, citric acid, acetic acid, quinine, urea, caffeine, sucrose octaacetate, propylthiouracil, phenylthiocarbamide, monosodium glutamate, and inosine monophosphate.
Study: NCT01243489

Intervention type: OTHER
Group type: OTHER
Intervention: compliance supporting measures
Description: Patients will be treated for a total of 12 months, 6 months without and 6 months with compliance supporting measures. Patient can choose between an information service Leben mit CML or the use of a daily diary

Intervention type: OTHER
Group type: OTHER
Intervention: compliance supporting measures
Description: Patients will be treated for a total of 12 months, 6 months without and 6 months with compliance supporting measures. Patient can choose between an information service Leben mit CML or the use of a daily diary
Study: NCT01761773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib
Description: 3 20-mg strength capsules (60 mg dose) administered as a single oral dose on Day 1 of study participation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib
Description: 3 20-mg strength capsules (60 mg dose) administered as a single oral dose on Day 1 of study participation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib
Description: 3 20-mg strength capsules (60 mg dose) administered as a single oral dose on Day 1 of study participation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib
Description: 3 20-mg strength capsules (60 mg dose) administered as a single oral dose on Day 1 of study participation.
Study: NCT01399216

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplement containing fucoidan, EPA, and DHA
Description: 75 mg fucoidan per day, for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: for 8 weeks
Study: NCT00459472

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: laparoscopic training curriculum
Description: All general surgery interns and PGY-2-5's already participate in a surgery training curriculum that includes lectures, surgery, laparoscopic training, attending surgeons evaluating performance of residents at the end of surgical procedures, written tests, and skills tests.
Study: NCT01293981

Intervention type: BIOLOGICAL
Intervention: PureGen Osteoprogenitor Cell Allograft
Description: PureGen Osteoprogenitor Cell Allograft.
Study: NCT03689712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC4419 90mg
Description: 60 minute IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 60 minute IV infusion
Study: NCT00483041

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Placebo administered as a single intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI528 9 mg/kg
Description: MEDI-528 at a dose of 9 mg/kg administered as a single intravenous infusion
Study: NCT03793491

Intervention type: OTHER
Intervention: TCI scale
Description: TCI scale : Evaluation of the patient's personality with the TCI before that the treatment by continuous infusion started.

Intervention type: OTHER
Intervention: PDQ-39 scale
Description: PDQ-39 scale: Comparison of life quality before and after the starting of he treatment by continuous infusion.
Study: NCT05661396

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Serious game rehabilitation
Description: Three patients received therapeutic serious game rehabilitation in addition to conventional rehabilitation. The serious game was proposed to be played three times per week for four weeks, for a total of 12 sessions, with 15 min per session (= 45 minutes per week).
Study: NCT02489812

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: This cross over trial aimed to analyze the use of music as a distraction resource during children dental treatment, evaluating their cardiac and respiratory frequency. Thirty-four children took part in this study, 16 boys and 18 girls, from 4 to 6 years old, with no previous dental experience, who had two carious lesions on occlusal surfaces of molars,
Study: NCT03119389

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Donning Non-Sterile Gloves without HH
Description: Current practice is to perform hand hygiene before donning of non-sterile gloves. In units assigned to the intervention, healthcare workers within the units will be educated that performing hand hygiene before donning non-sterile gloves is not necessary.
Study: NCT04065633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P3-Fast
Description: 200 mg (2 × 100 mg) PF-04965842 Phase 3 tablet formulation under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P3-Fast
Description: 200 mg (2 × 100 mg) PF-04965842 Phase 3 tablet formulation under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P3-Fast
Description: 200 mg (2 × 100 mg) PF-04965842 Phase 3 tablet formulation under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P3-Fast
Description: 200 mg (2 × 100 mg) PF-04965842 Phase 3 tablet formulation under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comm-Fast
Description: 200 mg PF-04965842 commercial tablet formulation under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comm-Fast
Description: 200 mg PF-04965842 commercial tablet formulation under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comm-Fast
Description: 200 mg PF-04965842 commercial tablet formulation under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comm-Fast
Description: 200 mg PF-04965842 commercial tablet formulation under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vari-Fast
Description: 200 mg PF-04965842 variant tablet formulation with slower dissolution under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vari-Fast
Description: 200 mg PF-04965842 variant tablet formulation with slower dissolution under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comm-Fed
Description: 200 mg PF-04965842 commercial tablet formulation under fed conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comm-Fed
Description: 200 mg PF-04965842 commercial tablet formulation under fed conditions
Study: NCT02545816

Intervention type: DEVICE
Group type: OTHER
Intervention: Bispectral index (BIS) EEG monitoring
Description: The Bispectral Index (BIS) EEG monitor is a simplified EEG monitoring device which was originally designed to monitor the depth of hypnosis during general anesthesia. It does this by analyzing changes in the processed electroencephalogram (EEG) which occur with the hypnotic state and creating a measure (or index) indicative of these changes. A number between 0 and 100 is derived, with values above 70 associated with an awake state. The monitor also provides a single channel EEG, an electromyogram (EMG) and an index of signal quality (SQI), all in real time.
Study: NCT00864851

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Replagal
Description: Intravenous (IV) infusion for 12 months

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Replagal
Description: Intravenous (IV) infusion for 12 months

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Replagal
Description: Intravenous (IV) infusion for 12 months
Study: NCT03166644

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Analgesia Nociception Index (ANI)-guided sufentanil administration
Description: One recent observational study showed that ANI-guided remifentanil administration during vascular surgery resulted in low opioid consumption and low postoperative pain rates.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Analgesia Nociception Index (ANI)-guided sufentanil administration
Description: One recent observational study showed that ANI-guided remifentanil administration during vascular surgery resulted in low opioid consumption and low postoperative pain rates.
Study: NCT02938273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avelumab
Description: Avelumab10 mg/kg i.v. at day -7, 7, 21,35 + maintenance therapy i.e avelumab10 mg/kg i.v. every 2 weeks for 6 months

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: 5 times a week, 7 weeks, total dose 70 Gy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: loading dose 400 mg/m2 i.v. day -7, 250 mg/m2 i.v weekly wk 1-7
Study: NCT00413010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: pregabalin 150-600 mg/day flexibly dosed for the first 6 weeks and fixed dosed for the last 2 weeks of total 8 weeks of double blind study period, + concurrent GAD treatment from the open-label study period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo + concurrent GAD treatment from the open-label study period
Study: NCT04427852

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 30 day Daily consumption of 1 serving of beef
Description: Beef patty will replace one of the participants protein servings each day for 30 days. Each serving is 114 grams of 90% lean ground sirloin given to participants as an uncooked frozen patty.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 30 day Daily consumption of 1 serving of the vegatable protein source
Description: Veggie patty will replace one of the participants protein servings each day for 30 days. No beef will be consumed during this period. The veggie patty is commercially available Morningstar veggie burger and is given to participants in commercial packaging as a frozen precooked patty.
Study: NCT04354272

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire for the satisfaction of patients consulting the odontological emergencies of the GHPS during COVID 19.
Study: NCT02663141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravitreal bevacizumab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02633553

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: adjuvant radiotherapy
Description: 50Gy/25Fx
Study: NCT01360177

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 124 PET/CT imaging
Description: Standard of Care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Na134I
Description: 25 to 150 mCi

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tri-iodothyronine
Description: 75 ug/8hr x 4 weeks; oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tri-iodothyronine
Description: 20 mg/day x 2
Study: NCT04621500

Intervention type: DRUG
Group type: OTHER
Intervention: cholecalciferol
Description: Enrolled subjects will supplement with vitamin D3 at 4,000 IU daily for one year

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard of Care Prostate Biopsy - collection of 13th core for RNA-seq
Description: RNA-seq analysis will be used to (a) identify changes in transcriptional profiles and biological pathways in the prostate between African American and Caucasian men and (b) compare Allostatic Load results to determine stress response and (c) identify changes in the molecular signature in relation to vitamin D levels

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard of Care Prostate Biopsies at baseline and after one year vitamin D3 supplementation
Description: Pathology results of the prostate biopsies will be analyzed for changes in the (a) Gleason Score (b) the number of positive cores (0 to 12) and (c) the highest percentage of positive core involvement (0 to 100%).

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Allostatic Load Measurements at baseline and after one year vitamin D3 supplementation
Description: Allostatic Load measurements to determine body stress compared at baseline and after one year of vitamin D3 supplementation. Also compared with RNA-seq results to determine stress response.
Study: NCT00875173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selenium
Description: selenium as a drug according to Brazilian regulation laws

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Selenium)
Description: Placebo with similar flavor, smell and colour.
Study: NCT02875730

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulse Sequence
Description: Cylindrical Navigator Preparatory Pulse Sequence
Study: NCT01836081

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Volume expansion
Study: NCT04622904

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine-magnesium infusion
Description: A bolus dose of lidocaine of 1.5 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Then, 3 mg/kg/h of lidocaine will be administered intraoperatively. A bolus dose of ketamine of 0.35 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Followingly, 0.2 mg/kg/h of ketamine will be administered intraoperatively diluted in a 60 mL syringe and administered at a rate of 20 mL/h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine-ketamine infusion
Description: A bolus dose of lidocaine of 1.5 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Then, 3 mg/kg/h of lidocaine will be administered intraoperatively. A bolus dose of magnesium of 50 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Followingly, 10 mg/kg/h of magnesium will be administered intraoperatively diluted in a 60 mL syringe and administered at a rate of 20 mL/h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine infusion
Description: A bolus dose of lidocaine of 1.5 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Then, 3 mg/kg/h of lidocaine will be administered intraoperatively. A bolus dose of normal saline 100 mL will be administered preoperatively within 10 minutes. Followingly, normal saline will be administered intraoperatively at a rate of 20 mL/h
Study: NCT03755908

Intervention type: DEVICE
Intervention: Forced oscillation technique (FOT)
Description: FOT will be measured using the TremoFlo C-100 Airwave Oscillometry System (Thorasys , Montreal, Quebec, Canada). R5, R20, R5-20 (resistances in the reported frequency), X5 (reactance in 5hz) and Ax5 (reactance area in 5hz) will be reported.
Study: NCT02875730

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CMRI
Description: Cardiac Magnetic Resonance Imaging
Study: NCT01234584

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spk
Description: implants using SPK Abutments
Study: NCT00849160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darunavir
Description: darunavir/r 800/100 mg once daily by oral route, 48 weeks of treatment
Study: NCT00860834

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asthma Coaching Program
Description: Parents will have access to an asthma coach for 12 months. Telephone calls between parents and coaches will occur anywhere from once a week to once a month.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Children of parents enrolled in the study will receive the normal asthma care that their pediatricians usually provide.
Study: NCT03567018

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI Scan
Description: Study participants will be scanned with a 3.0 Tesla Phillips Ingenia CX whole body clinical MRI system located at the Wright Center of Innovation at The Ohio State University Medical Center. Anatomical and angiographic MR images will be acquired for one of the most commonly used flap surgery donor perforators including but not limited to: the deep inferior epigastric perforators (DIEP); the superior gluteal arter perforators (SGAP); the inferior gluteal artery perforators (IGAP); the thoracodorsal artery perforators (TDAP); the anterolateral thigh perforators (ATL).
Study: NCT01234584

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CPK Abutments
Description: implants using CPK Abutments
Study: NCT01884571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: 20 mg, IV (in the vein) on day 1 and 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 125 mg, IV (in the vein) on day 1.